Dokument: Aberrante Methylierung des p16INK4a-Promotors als Tumormarker für die molekularzytologische Diagnostik des Lungenkarzinoms an Bronchialaspiraten

Titel:Aberrante Methylierung des p16INK4a-Promotors als Tumormarker für die molekularzytologische Diagnostik des Lungenkarzinoms an Bronchialaspiraten
URL für Lesezeichen:https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=10031
URN (NBN):urn:nbn:de:hbz:061-20090303-105059-9
Kollektion:Dissertationen
Sprache:Deutsch
Dokumententyp:Wissenschaftliche Abschlussarbeiten » Dissertation
Medientyp:Text
Autor: Krücken, Anne [Autor]
Dateien:
[Dateien anzeigen]Adobe PDF
[Details]739,7 KB in einer Datei
[ZIP-Datei erzeugen]
Dateien vom 12.01.2009 / geändert 12.01.2009
Beitragende:Prof. Dr. Böcking, Alfred [Gutachter]
Prof. Dr. Royer-Pokora, Brigitte [Gutachter]
Stichwörter:Methylierung; p16; Tumormarker
Dewey Dezimal-Klassifikation:600 Technik, Medizin, angewandte Wissenschaften » 610 Medizin und Gesundheit
Beschreibung:In der vorliegenden Arbeit wurde der Methylierungsstatus des p16INK4a-Promotors an Material der pulmonalen Exfoliativzytologie untersucht und seine Eignung als Tumormarker für die molekularzytologische Diagnostik des Lungenkarzinoms überprüft. Der Nachweis der p16INK4a-Promotor-Methylierung erfolgte an DNA aus Bronchialaspiraten (Bronchialsekrete, Bronchiallavagen, bronchoalveoläre Lavagen ) nach Bisulfitkonversion mittels quantitativer methylierungs-spezifischer PCR (QMSP). Dabei wurde Restmaterial der konventionellen zytologischen Diagnostik verwendet, sodass keine zusätzlichen, für den Patienten belastenden, Untersuchungen notwendig waren. Es wurden 237 Bronchialaspirate (176 Lungenkarzinom- und 61 Nicht-Tumor-Fälle) in die Untersuchung einbezogen.
Eine aberrante Promotor-Methylierung wurde insgesamt bei 18,2% der Bronchialaspirate von Tumorpatienten und in keinem der Bronchialaspirate der Nicht-Tumorpatienten nachgewiesen. Damit ist die Spezifität des Nachweises in p16INK4a-Promotormethylierung prinzipiell hinreichend, um sicher eine Tumordiagnose stellen zu können und p16INK4a als spezifischen Tumormarker für die Lungenkarzinom-Diagnostik zu nutzen. Insbesondere die Diagnosestellung von Plattenepithelkarzinomen scheint möglich. Bei 40,4% der Bronchialaspiraten von Patienten mit einem Plattenepithelkarzinom wurde eine aberrante Promotor-Methylierung von p16INK4a gefunden. Ob p16INK4a auch in der Krebsfrüherkennung nutzbar ist, muss noch in weiteren Studien untersucht werden. Aber schon jetzt zeichnet sich p16INK4a als vielversprechender molekularer Biomarker in der Lungenkrebsdiagnostik ab.
Quelle:Antequera F.,Boyes J., Bird A.: High levels of de novomethylation and altered chromatin structure at CpG islands in cell lines. Cell 62, 503-514 (1990) Ahrendt S.A., Chow J.T., Xu L.H., Yang S.C., Eisenberger C.F., Esteller M., Herman J.G., Wu L., Decker P.A., Jen J., Sidransky D.: Molecular detection of tumor cells in bronchoalveolar lavage fluids from patients with early stage lung cancer. J Natl Cancer Inst; 91: 332-339 (1999) Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland: Krebs in Deutschland. Saarbrücken 4. Ausgabe (2004) Attwood J.T., Yung R.L., Richardson B.C.:DNA methylation and the regulation of gene transcription. Cell Mol Life Sci.;59:241-257 (2002) Barrett M.T., Sanchez C.A., Prevo L.J., Wong D.J.,Galipeau P.C.,Paulson T.G.,Rabinovitch P.S.,Reid B.J.: Evolution of neoplastic cell lineages in Barrett oesophagus. Nat. Genet. 22, 106-109 (1999) Bastian P.J., Waha A., Müller S., von Rücker A.: Epigenetische Veränderungen in der Karzinogenese des Prostatakarzinoms. Deutsches Ärzteblatt.;27: Seite A-1981, B-1654, C-1588 (2004) Behn M.,Thiede C., Neubauer A.,Pankow W., Schuermann M.: Facilitated detection of oncogene mutations from exfoliated tissue material by PNA-mediated protocol. J Pathol 190:69-75 (2000) Belinsky S.A., Palmisano W.A., Gilliland F.D., Crooks L.A., Divine K.K., Winters S.A., Grimes M.J., Harms H.J., Tellez C.S., Smith T.M., Moots P.P., Lechner J.F., Stidley C.A., Crowell R.E.: Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res; 62: 2370-2377 (2002) Belinsky S.A., Liechty K.C., Gentry F.D., Wolf H.J., Rogers J., Vu K., Haney J., Kennedy T.C., Hirsch F.R., Miller Y., Franklin W.A., Herman J.G., Baylin S.B., Bunn P.A., Byers T.: Promotor hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 66, 3338-3344 (2006) Belinsky S.A., Grimes M.J., Casas E., Stidley C.A., Franklin W.A., Bocklage T.J., Johnson D.H., Schiller J.H.: Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br J Cancer. 23; 96(8), 1278-83.(2007) Bird A.,CpG-rich islands and the function of DNA methylation. Nature 321: 209-213 (1986) Bird A.: DNA methylation patterns and epigenic memory. Genes Dev 16: 6-21 (2002) Böcking A., Biesterfeld S., Chatelain R., Gien-Gerlach G., Esser E.: Diagnosis of bronchial carcinoma on sections of paraffin-embedded sputum. Sensitivity and specificity of an alternative to routine cytology. Acta Cytologica; 36(1): 37-47 (1992) Böcking A., Klose K.C., Kyll H.J., Hauptmann S.: Cytologic versus histologic evaluation of needle biopsy of the lung, hilum and mediastinum. Sensitivity, specificity and typing accuracy. Acta Cytologica; 39(3): 463-471 (1995) Böcking A.: Skriptum zum Kurs der Histopathologie für Zahnmediziner, 6. Auflage (1998) Brabender J, Usadel H, Danenberg KD, Metzger R, Schneider PM, Lord RV, Wickramasinghe K, Lum CE, Park JM, Salonga D, Singer J, Sidransky D, Hölscher AH, Meltzer SJ, Danenberg PV: Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 20: 3528-3532 (2001). Busch U., Pecoraro S.: Arbeitsschritte für die Durchführung einer PCR-Analyse. Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit (2007) Chan E.C., Lam S.Y., Tsang K.W., Lam B., Ho J.C., Fu K.H., Lam W.K., Kwong Y.L.: Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalveolar lavage. Clin Cancer Res 8: 3741-3746 (2002) Chen J.T., Chen Y.C., Wang Y.C., Tseng R.C., Chen C.Y., Wang Y.C.: Alterations of the p16INK4a gene in resected nonsmall cell lung tumors and exfoliated cells within sputum. Int J Cancer 98: 724-731 (2002) Clayton S.J., Scott F.M., Walker J., Callaghan K., Haque K., Liloglou T., Xinarianos G., Shawcross S., Ceuppens P., Field J.K. Fox J.C.: K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification. Clin Chem; 46: 1929-1938 (2000) Doerfler W.: DNA methylation and gene activity. Annu Rev Biochem 52;93-124 (1983) Eads C.A., Danenberg K.D., Kawakami K., Saltz L.B., Blake C., Shibata D., DanenbergP.V., Laird P.W.: MethyLight: a high-thoughput assay to measure DNA methylation. Nucleic Acids Res 28, E32 (2000) Esteller M.,Corn P.G., Baylin S.B., Herman J.G.: Agene hypermethylation profile of human cancer. Cancer Res 61, 3225-3229 (2001) Esteller M.: CpG island hypermethylation and tumor supressor genes.: a booming present, a brighter future. Oncogene. 21: 5427-5440 (2002) Frommer M., McDonald L.E.,Millar D.S., Collis C.M., Watt F.,Grigg G.W.,Molloy P.L.,Paul C.L.: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl Acad. Sci. USA 89, 1827-1831 (1992) Gilliland F.D., Harms H.J., Crowell R.E., Li Y.F., Willink R., Belinsky S.A.: Glutathione S-transferase P1 and NADPH quinone oxidoreductase polymorphisms are associated with aberrant promoter methylation of P16 (INK4a) and O(6)-methylguanine-DNA methyl-transferase in sputum. Cancer Res 62: 2248-2252 (2002) Gonzalez-Zulueta M.,Bender C.M., Yang A.S., Nguyen T.,Beart R.W., Van Tornout J.M., Jones P.A.:Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55, 4531-4535 (1995) Grote H.J, Schmiemann V., Kiel S., Böcking A., Kappes R., Gabbert H.E., Sarbia M.: Aberrant methylation of the APC gene promotor 1A in bronchial aspirates from patients with suspected lung cancer (2003 a) Grote H.J., Schmiemann V., Sarbia M., Böcking A.:DNA extraction from bronchial aspirates for molecular cytology: which method to take? Anal Cell Pathol 25; 83-88 (2003 b) Grote H.J., Schmiemann V., Geddert H., Kiel S., Kappes R., Rohr U., Gabbert H.E., Böcking A.: Aberrant promotor methylation of p16INK4a, RARB2 and SEMA3B in bronchial aspirates from patientswith susspectes lung cancer. Int. J. Cancer 110: 751-755 (2005) Grote H.J., Schmiemann V., Kazimirek M., Böcking A.:Quantitative methylation-specific PCR for the diagnosis of lung cancer. Pathologe 28(5): 377-83 (2007) Hajkova P., el-Maarri O., Engemann S., Oswald J., Olek A., Walter J.: DNA- methylation analysis by the bisulfite-assisted genomic sequencing method. Mol Biol. 200:143-154 (2002) Hanahan D.,Weinberg R.A., :The Hallmarks of Cancer. Cell 100, 57-70 (2000) Harden S.V., Tokumaru Y., Westra W.H., Goodman S., Ahrendt S.V., Yang S.C., Sidransky D.: Gene promoter hypermethylation in tumor and lymph nodes of stage I lung cancer patients. Clin Cancer Res 9: 1370-1375 (2003) Hecht, S.S.: Tobacco smoke carcinogens and lung cancer. J. Natl Cancer Inst. 91, 1194-1210 (1999) Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 6, 986-994 (1996) Henschke C.I., McCauley D.I.,Yankelevitz D.F., Naidich D.P., McGuiness G., Miettinen O.S., Libby D.M., Pasmantier M.W., Koizumi J., Altorki N.K., Smith J.P.:Early lung cancer action project:overall design and findings from baseline screening. Lacet 354: 99-105 (1999) Herman J.G.,Merlo A., Mao L., Lapidus R.G., Issa J.P., Davidson N.E., Sidransky D., Baylin S.B.: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55, 4525-4530 (1995) Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR : a novel PCR assay for methylation status of CpG islands Proc Natl Acad Sci USA 93: 9821-9826 (1996) Holland P.M., Abramson R.D., Watson R.,Gelfand D.H.: Detection of specific polymerase chain reaction product utilizing the 5´-3´exonuclease activity of thermus aquaticus DNA polymerase. Proc. Natl. Sci. USA 88, 7276-7280 (1991) Holliday R.: DNA methylation and epigenetic mechanisms. Cell Biophys 15:15-20 (1989) Jarmalaite S., Kannio A., Anttila S., Lazutka J.K., Husgafvel-Pursiainen K.: Aberrant p16 promotor methylation in smokers and former smokers with nonsmall cell lung cancer. Int J Cancer 106(6) ;913-8 (2003) Jones P.A., Laird P.W.: Cancer epigenetics comes of age. Nature Genet 21: 163-167 (1999) Jones P.A., Baylin S.B.: The fundamental role of epigenic events in cancer. Nat. Rev. Genet. 3, 415-428 (2002) Kashiwabara K.,Oyama T. et al.: Correlation between methylation status of the p16/CDKN2 gene and the exression of p16 and Rb proteins in primary non-small cell lung cancers. Int. J Cancer, 79:215-220 (1998) Kersting M., Friedl C., Kraus A., Behn M., Pankow W., Schuermann M.: Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol; 18: 3221-3229 (2000) Keshet I.,Lieman-Hurwitz J.,Cedar H.: DNA methylation affects the formation of active chromatin. Cell 44, 535-543 (1986) Kim D.H., Nelson H.H., Wiencke J.K., Zheng S., Christiani D.C., Wain J.C., Mark E.J., Kelsey K.T.: p16INK4a and histology-specific methylation of CpG islands by exposure to ta-bacco smoke in non-small cell lung cancer. Cancer Res; 61: 3419-3424 (2001) Kim J.S., Kim J.W., H. Joungho, Shim Y.M., Park J., Kim D.: Cohypermethylation of p16 and FHIT Promoters as a Prognostic Factor of Recurrence in Surgically Resected Stage I Non–Small Cell Lung Cancer. Cancer Res. 66 (2006) Konietzko, N., Fabel, H.(Hrsg.): Weißbuch Lunge. Thieme, Stuttgart New York (2000) Kreuzer M., Kreienbrock L., Gerken M., Heinrich J., Brüske-Hohlfeld I., Müller K.M., Wichmann H.E.: Risk factors for lung cancer in young adults. Am J Epidemiol; 147: 1028-1037 (1998) Kreuzer M.,Müller,K.M., Gerken,M.,Wichmann, H.E.:Lung cancer histologic types ande age of onset. Cancer 85, 1958-1965 (1999) Kurakawa E., Shimamoto T., Utsumi K., Hirano T., Kato H., Ohyashiki K.: Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer. Int J Oncol; 19: 277-281 (2001) Li E., Beard C., Jaenisch R.: Role for DNA methylation in genomic imprinting. Nature; 366: 362-365 (1993) Liu Y., An Q., Li L., Zhang D., Huang J., Feng X., Cheng S., Gao Y.: Hypermethylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications. Carcinogenesis ;24; 1897-1901 (2003) Mannino D.M., Ford E., Giobanni G.A., Thun M.: Lung cancer deaths in the United States from 1979 to 1992: an analysis using multiple-cause mortality data. Int J Epidemiol; 27: 159-166 (1998) Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C., Baylin S.B., Sidransky D.: 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1, 686-692 (1995) Mills N.E.,Fishman C.L., Scholes J.,Anderson S.E.,Rom W.N.,Jacobson D.R.: Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. J Natl Cancer Inst 87:1056-1060 (1995) Müller, K.M.:Neues zur Pathologie der Lungentumoren. Verh. Dtsch. Ges. Path. 83, 168-183 (1999) Osann, K.E.:Epidemiology of lung cancer. Curr. Opin. Pulm. Med. 4,198-204 (1998) Ota N., Kawakami K., Okuda T., Takehara A., Hiranuma C., Oyama K., Ota Y., Oda M., Watanabe G.:Prognostic significance of p16(INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis.1: Anticancer Res.; 26(5B) 3729-32. (2006) Palmisano W.A., Divine K.K., Saccomanno G., Gilliland F.D., Baylin S.B., Herman J.G., Belinsky S.A.: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res; 60: 5954-5958 (2000) Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000. The global picture. Eur J Cancer 37:4-66 (2001) Pfeifer G.P., Steigerwald S.D., Mueller P.R., Wold B., Riggs A.D.: Genomic sequencing and methylation analysis by ligation mediated PCR. Science; 246: 810-813 (1989) Riggs A.D., Pfeifer G.P.: X-chromosome inactivation and cell memory. Trends Genet. 8(5):169-74. (1992) Saccomanno G., Saunders R.P., Ellis H., Acher V.E., Wood B.G, Beckler P.A.: Concentration of carcinoma or atypical cells in sputum. Acta Cytol. 7:305-10 (1963) Sambrook J., Russel D.W.:Molecular Cloning-A Labaratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (2001) Sanchez-Cespedes M., Decker P.A., Doffek K.M., Esteller M., Westra W.H., Alawi E.A., Herman J.G., Demeure M.J., Sidransky D., Ahrendt S.A.: Increased Loss of Chromosome 9p21 but not p16 Inactivation in Primary Non-Small Cell Lung Cancer from Smokers.Cancer Research 61, 2092–2096 (2001) Schreiber G., McCrory D.C.: Performance characteristics of different modalities for diagnosis of suspected lung cancer: summery of published evidence. Chest 123 Suppl 1, 115S-128S (2003) Sherr C.J., G1 phase progression: cycling on cue. Cell 79, 551-555 (1994) Shivapurkar N., Stastny V., Suzuki M., Wistuba II., Li L., Zheng Y., Feng Z., Hol B., Prinsen C., Thunnissen F.B., Gazdar A.F. Application of a methylation gene panel by quantitative PCR for lung cancers.Cancer Lett. ;247(1):56-71. (2007) Solbin L.,Wittekind C. TNM classification of malignant tumors, 5th ed. New York: John Wiley, (1997) Somers V.A., van Henten A.M.J., ten Velde G.P.M., Arends J.W., Thunnissen F.B.J.M.: Additional value of K-ras point mutations in bronchial wash fluids for diagnosis of peripheral lung tumors. Eur Respir J 13: 1120-1124 (1999) Soria J.C., Rodriguez M., Liu D.D., Lee J.J., Hong W.K., Mao L.: Aberrant promoter methy-lation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res 62: 351-355 (2002) Srinivasan M.,Sedmak D., Jewell S.: Effect of fixtives and tissue processing on the content and integrity of nucleic acids. Am J pathol 161, 1961-1971 (2002) Swensen S.J., et al Lung cancer screening with CT: Mayo Clinic experience. Radiology 226, 756-761 (2003) Szyf M.: The DNA methylation maschienery as a target for anticancer therapy. Pharmacol Ther. 70:1-37 (1996) Thun, M.J., Lally, C.A., Flannery, J.T.,Calle, E.E., Flanders, W.D., Heath, C.W. Jr: Cigarette smoking and changesin the histopathologie of lung cancer. J. Natl Cancer Inst. 89, 1580-1586 (1997) Topaloglu O., Obaidul H., Tokumaru Y., Lee J., Ratovitski E., Sidransky D., Mool C.-S.: Detection of promoter hypermethylation of multiple genes in tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res; 10: 2284-2288 (2004) Toyooka S., Toyooka K.O., Maruyama R., Virmani A.K., Girard L., Miyajima K., Harada K., Ariyoshi Y., Takahashi T., Sugio K., Brambilla E., Gilcrease M., Minna J.D., Gazdar A.F.: DNA methylation profiles of lung tumors. Mol Cancer Ther 1: 61-67 (2001) Toyooka S.,Maruyama R., Toyooka K.O., McLarren D., Feng Z., Fukuyama Y., Virmani A.K., Zöchbauer-Müller S.,Tsukuda K., Sugio K.,Shimizu M., Shimizu K., et al.: Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int. J Cancer 103: 153-160 (2003) Travis WD ,Colby TV, Corrin B, Shimosato Y, Brambilla E, Sobin LH, eds. Histological typing of lung and pleural tumors. 3rd ed. WHO International Histological Classification of Tumors. Springer, Berlin-Heidelberg-New York (1999) Travis W.D., Brambilla E., Müller- Hermelink H.K., Harris C.C. eds.: WHO-Classification of tumors. Pathology of the Lung, Pleura, Thymus and Heart. IARC-Press, Lyon (2004) Tremblay K.D., Saam J.R., Ingram R.S., Tilghman S.M., Barolomei M.S.: A paternal-specific methylation imprint marks the allels of the mouse H19 gene. Nat Genet; 9: 407-413 (1995) Virmani A.K., Tsou J.A.,Siegmund K.D., Shen L.YY.C., Long T.I., Laird P.W., Gazdar A.F., Laird-Offringa I.A.: Hierarchical clustering of lung cancer cell lines unsing DNA methylation markers. Cancer Epidemiol Biomarkers Prevention 11, 291-297 (2002) Waki T.,Tamura G., Sato M., Motoyama T.: Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples. Oncogene 22: 4128-33 (2003) Weinberg RA: The retinoblastoma protein and cell cycle control Cell 81, 323-330 (1995) Xie G., Hou A., Li L., Gao Y., Cheng S.: Aberrant p16 promoter hypermethylation in bronchial mucosae as a biomarker for the early detection of lung cancer.Chinese Medical Journal; 119 (17), 1469-1472 (2006) Yakubowskaya M.S., Spiegelman V., Luo F.C., Malaev S., Salnev A., Zborovskaya I., Gasparyan A., Polotsy B., Machaladze Z., Trachtenberg A.C., Belitsky G.A., Ronai Z.: High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer. Int J Cancer 63: 810-814 (1995) Yanagawa N., Tamura G., Oizumi H., Takahashi N., Shimazaki Y., Motoyama T.: Pro-moter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci; 94: 589-592 (2003) Zheng S., Chen P., McMillan A., Lafuente A., Lafuente M.J., Ballesta A.,Trias M., Wiencke J.K.: Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors.Carcinogenesis. 21(11): 2057-64 (2000) Zöchbauer-Müller S., Fong K.M., Virmani A.K., Geradts J., Gazdar A.F., Minna J.D.:Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61: 249-255, (2001) Zöchbauer-Müller S., Minna J.D., Gazdar A.F.:Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist 7, 451-457 (2002) Zöchbauer-Müller S., Lam S., Toyooka S., Virmani A.K., Toyooka K.O., Seidl S., Minna J.D., Gazdar A.F.: Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer 107:612-616 (2003)
Fachbereich / Einrichtung:Medizinische Fakultät
Dokument erstellt am:03.03.2009
Dateien geändert am:12.01.2009
Promotionsantrag am:24.07.2008
Datum der Promotion:03.12.2008
english
Benutzer
Status: Gast
Aktionen